Therefore, the use of CCL2 siRNA, CCR2 siRNA, CCL2-neutralizing antibodies, CCL2 inhibitors or CCR2 antagonists has given promising results in the therapy of cancers such as breast cancer [248,249], glioma [250,251,252], and hepatocellular cancer [253] in laboratory animals inoculated with cancer cells. Here, CCR2 is linked to hepatocellular carcinoma.